Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 652017, 11 pages
http://dx.doi.org/10.1155/2015/652017
Research Article

BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells

1Department of Pathology & Cell Biology, University of South Florida, Tampa, FL 33612, USA
2Department of Medicine, University of Louisville, Louisville, KY 40202, USA
3Department of Obstetrics & Gynecology, University of South Florida, Tampa, FL 33612, USA
4H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Received 20 November 2014; Accepted 17 June 2015

Academic Editor: Seiichi Saito

Copyright © 2015 Kamisha T. Woolery et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. ACS, Cancer Facts & Figures 2013, American Cancer Society, Atlanta, Ga, USA, 2013.
  2. N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung, “Ovarian surface epithelium: biology, endocrinology, and pathology,” Endocrine Reviews, vol. 22, no. 2, pp. 255–288, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Kurman and I.-M. Shih, “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory,” The American Journal of Surgical Pathology, vol. 34, no. 3, pp. 433–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Dubeau, “The cell of origin of ovarian epithelial tumours,” The Lancet Oncology, vol. 9, no. 12, pp. 1191–1197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Lux, P. A. Fasching, and M. W. Beckmann, “Hereditary breast and ovarian cancer: review and future perspectives,” Journal of Molecular Medicine, vol. 84, no. 1, pp. 16–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Ford, D. F. Easton, D. T. Bishop, S. A. Narod, and D. E. Goldgar, “Risks of cancer in BRCA1-mutation carriers,” The Lancet, vol. 343, no. 8899, pp. 692–695, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Whittemore, G. Gong, and J. Itnyre, “Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer,” The American Journal of Human Genetics, vol. 60, no. 3, pp. 496–504, 1997. View at Google Scholar · View at Scopus
  8. P. B. Mullan, J. E. Quinn, and D. P. Harkin, “The role of BRCA1 in transcriptional regulation and cell cycle control,” Oncogene, vol. 25, no. 43, pp. 5854–5863, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Linger and P. A. Kruk, “BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications,” The FEBS Journal, vol. 277, no. 15, pp. 3086–3096, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Satagopan, J. Boyd, N. D. Kauff et al., “Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations,” Clinical Cancer Research, vol. 8, no. 12, pp. 3776–3781, 2002. View at Google Scholar · View at Scopus
  11. N. C. Johnson and P. A. Kruk, “BRCA1 zinc RING finger domain disruption alters caspase response in ovarian surface epithelial cells,” Cancer Cell International, vol. 2, no. 1, article 7, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. N. C. Johnson, H. C. Dan, J. Q. Cheng, and P. A. Kruk, “BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells,” Experimental Cell Research, vol. 298, no. 1, pp. 9–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. O'Donnell, N. C. Johnson, T. D. Turbeville, M. Y. Alfonso, and P. A. Kruk, “BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells,” In Vitro Cellular & Developmental Biology—Animal, vol. 44, no. 8-9, pp. 357–367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Surowiak, V. Materna, M. Drag-Zalesinska et al., “Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates,” International Journal of Gynecological Pathology, vol. 25, no. 2, pp. 131–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Salazar, A. K. Godwin, M. B. Daly et al., “Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies,” Journal of the National Cancer Institute, vol. 88, no. 24, pp. 1810–1820, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Auersperg, S. Maines-Bandiera, J. H. Booth, H. T. Lynch, A. K. Godwin, and T. C. Hamilton, “Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 173, no. 2, pp. 558–565, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. H. G. Dyck, T. C. Hamilton, A. K. Godwin, H. T. Lynch, S. Maines-Bandiera, and N. Auersperg, “Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer,” International Journal of Cancer, vol. 69, no. 6, pp. 429–436, 1996. View at Google Scholar · View at Scopus
  18. R. B. Ness, J. A. Grisso, C. Cottreau et al., “Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer,” Epidemiology, vol. 11, no. 2, pp. 111–117, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Sueblinvong and M. E. Carney, “Current understanding of risk factors for ovarian cancer,” Current Treatment Options in Oncology, vol. 10, no. 1-2, pp. 67–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. McSorley, A. J. Alberg, D. S. Allen et al., “C-reactive protein concentrations and subsequent ovarian cancer risk,” Obstetrics and Gynecology, vol. 109, no. 4, pp. 933–941, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. B. Ness and F. Modugno, “Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers,” European Journal of Cancer, vol. 42, no. 6, pp. 691–703, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Fuseya, A. Horiuchi, A. Hayashi et al., “Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis,” Human Pathology, vol. 43, no. 11, pp. 1964–1972, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ogawa, T. Kaku, S. Amada et al., “Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study,” Gynecologic Oncology, vol. 77, no. 2, pp. 298–304, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kobayashi, K. Sumimoto, N. Moniwa et al., “Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan,” International Journal of Gynecological Cancer, vol. 17, no. 1, pp. 37–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Melin, P. Sparén, I. Persson, and A. Bergqvist, “Endometriosis and the risk of cancer with special emphasis on ovarian cancer,” Human Reproduction, vol. 21, no. 5, pp. 1237–1242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. I. M. Zardawi, “Primary fallopian tube carcinoma arising in the setting of chronic pelvic inflammatory disease,” Case Reports in Medicine, vol. 2014, Article ID 645045, 7 pages, 2014. View at Publisher · View at Google Scholar
  27. C. B. Rasmussen, M. T. Faber, A. Jensen et al., “Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors,” Cancer Causes & Control, vol. 24, no. 7, pp. 1459–1464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. T. Casagrande, M. C. Pike, R. K. Ross, E. W. Louie, S. Roy, and B. E. Henderson, “Incessant ovulation and ovarian cancer,” The Lancet, vol. 314, no. 8135, pp. 170–173, 1979. View at Publisher · View at Google Scholar · View at Scopus
  29. H. O. Osterholzer, J. H. Johnson, and S. V. Nicosia, “An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation,” Biology of Reproduction, vol. 33, no. 3, pp. 729–738, 1985. View at Publisher · View at Google Scholar · View at Scopus
  30. S. V. Nicosia, R. J. Narconis, and B. O. Saunders, “Regulation and temporal sequence of surface epithelium morphogenesis in the postovulatory rabbit ovary,” Progress in Clinical and Biological Research, vol. 296, pp. 111–119, 1989. View at Google Scholar · View at Scopus
  31. A. Macciò and C. Madeddu, “Inflammation and ovarian cancer,” Cytokine, vol. 58, no. 2, pp. 133–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. S. Fleming, C. R. Beaugié, I. Haviv, G. Chenevix-Trench, and O. L. Tan, “Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses,” Molecular and Cellular Endocrinology, vol. 247, no. 1-2, pp. 4–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. H. Lawal and C. B. Lynch, “Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer,” British Journal of Obstetrics and Gynaecology, vol. 103, no. 9, pp. 931–932, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Abboud, E. Attieh, D. Atallah, A. Kessrouani, and G. Chaoul, “Three cases of ovarian cancer after ovulation induction for infertility,” Contraception, Fertililite, Sexualite, vol. 25, no. 1, pp. 64–65, 1997. View at Google Scholar
  35. C. A. Dinarello, “Biologic basis for interleukin-1 in disease,” Blood, vol. 87, no. 6, pp. 2095–2147, 1996. View at Google Scholar · View at Scopus
  36. E. Stylianou and J. Saklatvala, “Interleukin-1,” International Journal of Biochemistry and Cell Biology, vol. 30, no. 10, pp. 1075–1079, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Messeguer, R. Escudero, D. Farré, O. Núñez, J. Martínez, and M. M. Albà, “PROMO: detection of known transcription regulatory elements using species-tailored searches,” Bioinformatics, vol. 18, no. 2, pp. 333–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Farré, R. Roset, M. Huerta et al., “Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN,” Nucleic Acids Research, vol. 31, no. 13, pp. 3651–3653, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. O'Donnell, R. J. Linger, and P. A. Kruk, “BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells,” Gynecologic Oncology, vol. 116, no. 2, pp. 262–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. B. C. Vanderhyden, T. J. Shaw, and J.-F. Ethier, “Animal models of ovarian cancer,” Reproductive Biology and Endocrinology, vol. 1, article 67, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Jiang, B. O. Saunders, E. Haller, S. Livingston, S. V. Nicosia, and W. Bai, “Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells,” In Vitro Cellular and Developmental Biology Animal, vol. 39, no. 7, pp. 304–312, 2003. View at Google Scholar · View at Scopus
  42. C. H. Holschneider and J. S. Berek, “Ovarian cancer: epidemiology, biology, and prognostic factors,” Seminars in Surgical Oncology, vol. 19, no. 1, pp. 3–10, 2000. View at Google Scholar · View at Scopus
  43. C. M. Counter, H. W. Hirte, S. Bacchetti, and C. B. Harley, “Telomerase activity in human ovarian carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 2900–2904, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. S. J. Ramus and S. A. Gayther, “The contribution of BRCA1 and BRCA2 to ovarian cancer,” Molecular Oncology, vol. 3, no. 2, pp. 138–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Perrin-Vidoz, O. M. Sinilnikova, D. Stoppa-Lyonnet, G. M. Lenoir, and S. Mazoyer, “The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons,” Human Molecular Genetics, vol. 11, no. 23, pp. 2805–2814, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Sylvain, S. Lafarge, and Y.-J. Bignon, “Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line,” International Journal of Oncology, vol. 20, no. 4, pp. 845–853, 2002. View at Google Scholar · View at Scopus
  47. M. Thangaraju, S. H. Kaufmann, and F. J. Couch, “BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33487–33496, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M.-K. Kim, K. Kim, J. Y. Han, J. M. Lim, and Y. S. Song, “Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer,” Genes and Nutrition, vol. 6, no. 2, pp. 109–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. S. S. Seo, Y. S. Song, D.-H. Kang et al., “Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer,” Gynecologic Oncology, vol. 92, no. 3, pp. 927–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. T. V. Clendenen, E. Lundin, A. Zeleniuch-Jacquotte et al., “Circulating inflammation markers and risk of epithelial ovarian cancer,” Cancer Epidemiology Biomarkers & Prevention, vol. 20, no. 5, pp. 799–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Denkert, I. Koch, S. Berger, M. Köbel, A. Siegert, and S. Hauptmann, “Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells,” Cancer Letters, vol. 195, no. 1, pp. 101–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Yellapa, P. Bitterman, S. Sharma et al., “Interleukin 16 expression changes in association with ovarian malignant transformation,” The American Journal of Obstetrics and Gynecology, vol. 210, no. 3, pp. 272.e1–272.e10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Baandrup, M. T. Faber, U. J. Christensen et al., “Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies,” Acta Obstetricia et Gynecologica Scandinavica, vol. 92, no. 3, pp. 245–255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. M. A. Murphy, B. Trabert, H. P. Yang et al., “Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review,” Cancer Causes & Control, vol. 23, no. 11, pp. 1839–1852, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. K. D. Crew and A. I. Neugut, “Aspirin and NSAIDs: effects in breast and ovarian cancers,” Current Opinion in Obstetrics and Gynecology, vol. 18, no. 1, pp. 71–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. S. S. Chen, A. Michael, and S. A. Butler-Manuel, “Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals,” Discovery Medicine, vol. 13, no. 68, pp. 7–17, 2012. View at Google Scholar
  58. S. Chen, M. Cooper, M. Jones et al., “Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals,” Cell Biology and Toxicology, vol. 27, no. 2, pp. 133–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Luo, M. K. Daddysman, G. O. Rankin, B.-H. Jiang, and Y. C. Chen, “Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc,” Cancer Cell International, vol. 10, article 16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Luo, B.-H. Jiang, S. M. King, and Y. C. Chen, “Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids,” Nutrition and Cancer, vol. 60, no. 6, pp. 800–809, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. H. Seo, K. J. Jeong, W. J. Oh et al., “Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin,” Cancer Letters, vol. 288, no. 1, pp. 50–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. C. A. Dinarello, A. Simon, and J. W. M. van der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. J.-H. Kim, C.-H. Yu, J.-Y. Yhee, K.-S. Im, and J.-H. Sur, “Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours,” Journal of Comparative Pathology, vol. 142, no. 2-3, pp. 177–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. I. G. Schauer, J. Zhang, Z. Xing et al., “Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts,” Neoplasia, vol. 15, no. 4, pp. 409–420, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. C. A. Dinarello, “The paradox of pro-inflammatory cytokines in cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 307–313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Lewis, S. Varghese, H. Xu, and H. R. Alexander, “Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment,” Journal of Translational Medicine, vol. 4, article 48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Stadlmann, A. Amberger, J. Pollheimer et al., “Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions,” Gynecologic Oncology, vol. 97, no. 3, pp. 784–789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Watanabe, T. Hashimoto, T. Sugino et al., “Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination,” Journal of Ovarian Research, vol. 5, no. 1, article 7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Mustea, C. Pirvulescu, D. Könsgen et al., “Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer,” Cytokine, vol. 42, no. 1, pp. 77–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Macciò and C. Madeddu, “The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review,” Journal of Molecular Medicine, vol. 91, no. 12, pp. 1355–1368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. M. M. Moradi, L. F. Carson, J. B. Weinberg, A. F. Haney, L. B. Twiggs, and S. Ramakrishnan, “Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer,” Cancer, vol. 72, no. 8, pp. 2433–2440, 1993. View at Google Scholar · View at Scopus
  72. K. T. Woolery, M. S. Hoffman, J. Kraft, S. V. Nicosia, A. Kumar, and P. A. Kruk, “Urinary interleukin-1β levels among gynecological patients,” Journal of Ovarian Research, vol. 7, article 104, 2014. View at Publisher · View at Google Scholar
  73. T. R. Rebbeck, N. Mitra, F. Wan et al., “Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer,” The Journal of the American Medical Association, vol. 313, no. 13, pp. 1347–1361, 2015. View at Publisher · View at Google Scholar